Delcath Systems Q3 2026 earnings

DCTH · 2026-11-09 08:02 BMO ET · 8-K on SEC · 10-Q on SEC

Revenue and adjusted EBITDA growth accelerated in Q3, with net income turning positive year-over-year.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$35.1M+70.4%+20.6%Ex. 99.1, income statement
EPS (GAAP)$0.17+0.15+0.10Ex. 99.1, income statement
EPS (adjusted)N/AN/AN/AEx. 99.1, income statement
Net income$6.95M+737.3%+160.9%Ex. 99.1, income statement
Adj. EBITDA$11.5M+116.8%+51.3%Ex. 99.1, income statement
Adj. EBITDA margin32.7%+27.2 pp+3.1 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
HEPZATO KIT$32.7M+69.4%93.2%U.S. sales
CHEMOSAT$2.4M+84.6%6.8%European sales

Margins and costs

  • Gross margin 89% (prior 87%, change +2.0 pp)
  • Operating expenses $24.1M (+31.4% YoY)
  • One-offs in the quarter Stock-based compensation expense of $4.23M; Interest income of $0.85M
  • Effective tax rate 12.7% (prior-year -121.3%, year-to-date 16.3%)
  • Non-GAAP bridge Adds back stock-based compensation, depreciation, and interest income to GAAP net income.

KPIs

MetricActualPrior quarterPrior yearChange
Cash provided by operations$8.2M$5.7M$4.8M+43.9% vs prior quarter
Cash and investments$104.3M$95.9MN/A+8.7% vs prior quarter
HEPZATO volume growth72%30%N/A+42 pp vs prior quarter

Guidance

MetricGuidePrior guideChange
Total HEPZATO KIT and CHEMOSAT revenue$115M to $117M$104M to $108M+11% to +8.3%
Full year gross margins87% to 89%86% to 89%No change

What drove it

  • Revenue story Total revenue grew 70.4% YoY, driven by 69.4% growth in HEPZATO KIT and 84.6% growth in CHEMOSAT.
  • EPS story EPS growth was driven by higher revenue, improved operating margins, and a lower tax rate.
  • One-off check Stock-based compensation expense of $4.23M and interest income of $0.85M.

The good

  • Adjusted EBITDA of $11.5M (+116.8% YoY)
  • Net income of $7.0M (+737.3% YoY)
  • Cash and investments of $104.3M

The bad

  • SG&A expenses increased 26.7% YoY to $13.1M
  • R&D expenses increased 37.8% YoY to $11.0M

The ugly

  • none

Open questions

  • The reconciliation of GAAP to Non-GAAP adjusted EBITDA is truncated.
  • The prior year tax rate was negative (-121.3%) due to a tax benefit.
Full release

Delcath Systems (DCTH) earnings release, November 9, 2026

Delcath Systems, Inc. (DCTH) · Form 8-K, Item 2.02 · Filed · SEC filing

Delcath Systems Reports Third Quarter 2026

Results and Business Highlights

Increases 2026 Revenue Guidance to a Range of $115 million to $117 million

Conference Call Today at 8:30 a.m. Eastern Time

QUEENSBURY, NY – November 9, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Results

• Total revenue of $35.1 million, compared with $20.6 million in the third quarter of 2025

◦ HEPZATO KIT™ revenue of $32.7 million, compared to $19.3 million in the third quarter of 2025

◦ CHEMOSAT® revenue of $2.4 million, compared to $1.3 million in the third quarter of 2025

• Gross margins of 89%, compared to 87% in the third quarter of 2025

• Net income of $7.0 million, compared to $0.8 million in the third quarter of 2025

• Non-GAAP adjusted EBITDA of $11.5 million, compared to $5.3 million in the third quarter of 2025

• Cash provided by operations of $8.2 million in the quarter; compared to $4.8 million in the third quarter of 2025

• Cash and investments of $104.3 million as of September 30, 2026; and no debt

Business Highlights

• Currently 33 active treatment centers

• Approximately 72% growth in HEPZATO volume in the third quarter 2026 compared to the third quarter 2025

• Advanced the global Phase 2 DELUMA trial (NCT06875128), evaluating HEPZATO in combination with standard-of-care therapy versus standard of care alone in liver-dominant HER2-negative metastatic breast cancer; first patient dosed July 9, 2026, at the European Institute of Oncology in Milan, Italy. The randomized trial is designed to enroll approximately 90 patients at more than 20 U.S. and European sites.

“We are pleased with the continued momentum in our business, with meaningful progress across both commercial operations and clinical development,” said Gerard Michel, Chief Executive Officer of Delcath Systems. “Growing physician experience with HEPZATO, strong engagement across our treatment center network, and increasing interest in its use alongside systemic therapies reinforce our confidence in the long-term opportunity. We are also expanding our pipeline, with a planned IND submission for cholangiocarcinoma in early 2027 and, pending FDA agreement, completion of ongoing preclinical development of an oxaliplatin-based PHP product by mid-2027.”

2026 Full Year Financial Guidance

The Company’s financial outlook for fiscal year 2026:

• Total HEPZATO KIT and CHEMOSAT revenue to range from $115 million to $117 million, reflecting an increase in HEPZATO KIT volume of at least 41% over 2025

• Full year gross margins in the range of 87% to 89%

• Positive adjusted EBITDA¹

Exhibit 99.1

Third Quarter 2026 Results

Total revenue for the quarter ending September 30, 2026 was $35.1 million compared to $20.6 million for the same period in the prior year. Revenue in the quarter includes sales of $32.7 million of HEPZATO in the U.S. and $2.4 million of CHEMOSAT in Europe.

Research and development expenses for the quarter ending September 30, 2026, were $11.0 million compared to $8.0 million for the same period in the prior year. The increase is primarily due to increased clinical headcount and increased clinical trial activity.

Selling, general and administrative expenses for the quarter ended September 30, 2026, were $13.1 million compared to $10.3 million for the same period in the prior year. The increase is primarily due to continued commercial expansion activities.

Net income was $7.0 million for the quarter ended September 30, 2026, compared to $0.8 million for the same period in the prior year.

Non-GAAP adjusted EBITDA for the quarter ended September 30, 2026 was $11.5 million compared to adjusted EBITDA of $5.3 million for the same period in the prior year. A table reconciling non-GAAP measures is included in this press release for reference.

As of September 30, 2026, the Company had $104.3 million in cash and investments, and no debt.

Conference Call Information

To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.

Event Date: Monday, November 9, 2026

Time: 8:30 AM Eastern Time

Participant Numbers:

Toll Free: 1-800-717-1738

International: 1-646-307-1865

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1767384&tp_key=cbc23b55c8

A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website https://investors.delcath.com/news-events/events-and-presentations.

GAAP v. Non-GAAP Measures

Delcath’s reported earnings are prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and represent earnings as reported to the Securities and Exchange Commission. Delcath has provided in this release certain financial information that has not been prepared in accordance with GAAP. Delcath’s management believes that the non-GAAP adjusted EBITDA described in this release, which includes adjustments for specific items that are generally not indicative of our core operations, provides additional information that is useful to investors in understanding Delcath’s underlying performance, business and performance trends, and helps facilitate period-to-period comparisons and comparisons of its financial measures with other companies in Delcath’s industry. However, the non-GAAP financial measures that Delcath uses may differ from measures that other companies may use. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP.

About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT... (truncated)cts, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.²

Exhibit 99.1

In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath’ s proprietary HDS. The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.

In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

Financial statements

Income Statement

Three months ended September 30, — (in thousands, except share and per share data)

Three months ended September 30, – 2026Three months ended September 30, – 2025Nine months ended September 30, – 2026Nine months ended September 30, – 2025
Product revenue35,10220,56389,22964,503
Cost of goods sold-3,918-2,624-10,639-8,787
Gross profit31,18417,93978,59055,716
Operating expenses:
Research and development expenses11,0117,98631,21519,875
Selling, general and administrative expenses13,05710,34139,50132,997
Total operating expenses24,06818,32770,71652,872
Operating income7,116-3887,8742,844
Interest income8527962,4202,063
Other expense-1-33-76-63
Income before income taxes7,96737510,2184,844
Income tax expense (benefit)1,015-4551,668248
Net income6,9528308,5504,596
Other comprehensive income (loss):
Unrealized gain on investments adjustments115296-135592
Foreign currency translation adjustments-4-13-71201
Total comprehensive income7,0631,1138,3445,389
Common share data:
Basic income per common share0.190.020.240.13
Weighted average number of basic shares outstanding36,074,34836,383,27735,996,01935,610,619
Diluted income per common share0.170.020.210.12
Weighted average number of dilutive shares outstanding41,019,55340,056,81440,059,10339,949,941

Income Statement

Three months ended September 30, — (in thousands)

Three months ended September 30, – 2026Three months ended September 30, – 2025Nine months ended September 30, – 2026Nine months ended September 30, – 2025
Net income6,9528308,5504,596
Stock-based compensation expense4,2335,64814,29719,720
Depreciation15364368158
Interest income-852-796-2,420-2,063
Income tax expense1,015-4551,668248
Adjusted EBITDA (Non-GAAP)11,5015,29122,46322,659

Balance Sheet

(in thousands, except share and per share data)

September 30, 2026December 31, 2025
Current assets
Cash and cash equivalents55,53843,454
Short-term investments48,77747,582
Accounts receivable20,21411,744
Inventories10,50110,252
Prepaid expenses and other current assets6,5256,498
Total current assets141,555119,530
Property, plant and equipment, net5,1273,166
Right-of-use assets2,408936
Total assets149,090123,632
Current liabilities
Accounts payable3,4752,658
Accrued expenses9,3518,191
Lease liabilities, current196101
Total current liabilities13,02210,950
Lease liabilities, non-current2,212835
Other liabilities, non-current319628
Total liabilities15,55312,413
Stockholders’ equity
Common stock, $0.01 par value; 80,000,000 shares authorized; 34,771,239 shares and 34,691,671 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively348347
Additional paid-in capital653,118639,145
Accumulated deficit-520,298-528,848
Accumulated other comprehensive income369575
Total stockholders’ equity133,537111,219
Total liabilities and stockholders’ equity149,090123,632

Cash Flow

From the 10-Q · Nine months ended September 30, — (in thousands)

Nine months ended September 30, – 2026Nine months ended September 30, – 2025
Cash flows from operating activities:
Net income8,5504,596
Adjustments to reconcile net income to net cash provided by operating activities:
Share-based compensation expense14,29719,720
Depreciation expense368158
Amortization of Right-of-Use Asset13282
Amortization of premiums and discounts on marketable securities-1,328-1,238
Changes in operating assets and liabilities:
Prepaid expenses and other assets-27-3,919
Accounts receivable-8,470-2,861
Inventories-249-3,812
Accounts payable and accrued expenses1,9771,800
Other liabilities, non-current-505-258
Net cash provided by operating activities14,74514,268
Cash flows from investing activities:
Purchase of investments-64,195-61,432
Maturities of investments64,19336,400
Purchase of property, plant and equipment-2,333-997
Net cash used in investing activities-2,335-26,029
Cash flows from financing activities:
Proceeds from the issuance of common stock relating to the employee stock purchase plan696481
Proceeds from exercise of warrants16,158
Proceeds from exercise of stock options1,9924,353
Repurchase and retirement of common stock-3,011
Net cash (used in) provided by financing activities-32320,992
Foreign currency effects on cash-3170
Net increase in total cash12,0849,401
Total Cash and Cash Equivalents:
Beginning of period43,45432,412

Safe Harbor / Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This press release contains forward-looking statements, including the Company’s statements regarding the possible synergy seen in the successful Phase 2 CHOPIN Trial being transferable to clinical practice; Company’s 2026 financial outlook, which are subject to certain risks and uncertainties, that can cause actual results to differ materially from those described. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the Company’s commercialization plans and its ability to successfully commercialize the HEPZATO KIT; contributions to adjusted EBITDA; the Company’s successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of the Company and those of its third-party suppliers/manufacturers; the Company’s successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; the Company’s ability to obtain reimbursement for the HEPZATO KIT; and the Company’s ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT. For additional information about these factors, and others that may impact the Company, please see the Company’s filings with the Securities and Exchange Commission, including those on Forms 10-K, 10-Q, and 8-K. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Investor Relations Contact:

ICR Healthcare investorrelations@delcath.com³

Exhibit 99.1

DELCATH SYSTEMS, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

(in thousands, except share and per share data)⁴

Exhibit 99.1

DELCATH SYSTEMS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Income

(Unaudited)

(in thousands, except share and per share data)

DELCATH SYSTEMS, INC.

Reconciliation of Reported Net Income (GAAP) to Adjusted EBITDA (NON-GAAP Measure)

(Unaudited)

(in thousands)⁵

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Delcath Systems earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.